News Catalent acquires gene therapy specialist Paragon for $1.2bn Drug delivery technology provider Catalent is to acquire gene therapy company Paragon for $1.2 billion.
R&D On genomics, NGS, and doing much more good than bad, with Ma... Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
